The tax tribunal noted that recombinant had the advantages over blood-derived factor concentrate of being available in an unlimited supply, being a renewable source, and having freedom from blood-borne viral contamination. By comparison, purified plasma derived Factor 8 "might contain low levels of viral contamination."